The Great Resignation is becoming a “great midlife crisis”

Older, more tenured people are increasingly quitting their jobs.By Rani Molla@ranimolla  Apr 30, 2022, 8:00am EDT

With prices soaring and analysts predicting a recession on the horizon, it might not seem like the best time to quit your job. But that’s not keeping American workers, especially older, more tenured ones, from doing so.

Higher-paid workers are increasingly quitting their jobs, as the Great Resignation — also known as the Great Reshuffle — enters its second year. Earlier in the pandemic, the trend was led by younger, less-tenured workers in low-paying industries like retail, food service, and health care. Now, the main growth in quit rates is coming from older, more tenured workers in higher-paid industries like finance, tech, and other knowledge worker fields, according to data from two separate human resources and analytics companies. These workers say they are searching for less tangible benefits like meaning and flexibility.

That changing composition of who is quitting paints an increasingly complicated picture of the state of work in America and suggests that while quit rates have decreased slightly from their highs last year, the phenomenon is not going away just yet.

“The Great Resignation is almost like a train, where it’s built all this momentum and it’s hard to slow down, but certain workers are getting off the train and new workers are coming on,” said Luke Pardue, an economist at Gusto, which provides payroll, benefits, and human resource management software to small- and medium-sized businesses.

Rates of quits are always highest among younger, less senior workers — those who tend to be less invested in their jobs and whose lives are less stable. This was true during the early stages of the pandemic when these workers quit their jobs amid heightened demand to eke out better wages and conditions elsewhere (though those gains are unlikely to be permanent). But those quit rates have been declining. Data from Gusto, which typically works with companies that have around 25 employees, shows that the average tenure of people who quit has grown in every age group and in nearly every industry. In other words, older people who’ve worked at a job longer are also quitting.

A similar change is happening at bigger companies, according to data from people analytics provider Visier.https://datawrapper.dwcdn.net/ceS03/1/https://datawrapper.dwcdn.net/yDfl6/1/

Between the first quarter of 2021 and 2022, the greatest growth in resignations was among people aged 40 to 60 and those with a tenure of more than 10 years, a Visier dataset from companies with over 1,000 employees shows. Older and more tenured people are especially likely to be quitting in knowledge worker industries like finance and tech.

Their reasons are myriad.

“Don’t look for one thing that’s driving the Great Resignation,” Ian Cook, Visier’s vice president of people analytics, told Recode. “It’s actually made up from a combination of different patterns and will continue to change as the labor market changes and as the economic recovery changes.”

Among the more financially stable set, quits are being driven by everything from a desire to continue working remotely to a greater search for meaning to simply having the means to do so.

Columbia Business School professor Adam Galinsky calls this iteration of the Great Resignation the “great midlife crisis.”

“At the midpoint of life, we become aware of our own mortality, and it allows us to reflect on what really matters to us,” said Galinsky. The pandemic has amplified that effect. “A global pandemic obviously makes people reflect on their own mortality in terms of being afraid of dying themselves or having a loved one or family and colleagues pass away.”

Importantly, the people who quit to hold out for the jobs they want or forgo work entirely are usually the ones with the financial means to do so.

Galinsky, who is currently on sabbatical in Hawaii, says he’s seen it among his peers and among other high-earning knowledge workers now working from his island getaway. He mentioned a Bloomberg employee who quit after the finance publication called workers back to the office and who now works on a pasta truck.

Such workers, either due to savings or a spouse’s income, have the freedom to look for other work, including gig work or starting their own business. A Gusto survey of new businesses shows that they’ve shifted from e-commerce startups earlier in the pandemic to more professional services, like, say, an accountant starting her own firm rather than working for someone else.

Many of these workers, especially those who are older and more stable in their careers, now have the perspective to consider what they really want out of their lives and work.

After more than two years of successfully working from home, many knowledge workers are loath to come back to the office, and some are jumping ship if they feel they have to do so. That makes sense. Data from Slack’s ongoing survey of 10,000 knowledge workers just found that with a third of them now back in the office five days a week, their work-related stress and anxiety has reached its highest level since the survey began in 2020.

Growth in knowledge worker quits also might just simply be a case of people copying one another.

“Workers who have this experience, that switched a job, that became more flexible, talk about it and how they had a great experience, and that leads their neighbor or their friend to do the same,” Pardue said.

They’re also quitting because there are a lot of jobs out there for them. The number of business and professional services job openings is at a record high, according to Bureau of Labor Statistics data. According to job site Indeed, the number of high-paid job postings has not cooled as much as postings for low-paid jobs (postings for both remain above pre-pandemic levels).

So while the future might look grim, the present looks just fine for these workers, who are confident in the current tight job market. As Galinsky put it, “People believe less in global warming on days it snows.”

Older workers in higher-paid industries are joining the Great Resignation – Vox

Inflation, supply chain shortages making it harder, more expensive to obtain needed medical equipment

Exam tables are backlogged for four to five months

By Daniella Genovese FOXBusiness

The ongoing supply chain disruptions have made it difficult for medical officials to get their hands on much-needed equipment from wheelchairs, crutches to canes and even exam tables. 

The war in Ukraine is only exacerbating those supply chain issues – which persisted over the past two years – because Russia is a major producer of nickel, chrome and steel, Cindy Juhas, chief strategy officer of CME Corp. told FOX Business. 

As a result, it’s taking “two to three times longer to get things,” she said. And when they come in, the cost for these products have surged due in part because of an increase in freight and raw material costs. 

CME is the largest equipment-focused national medical distributor in the U.S., offering more than 2 million products from more than 2,000 manufacturers.

stretchers

Stretchers assembled by CME.  (CME Corp.   )

“So far, in 2022, we’re already seeing annual price increases that are up to quadruple or even five times higher than usual,” Juhas said. The company reviewed 339 pricing contracts from a total of 167 top medical vendors.

Juhas said the manufacturer for one of CME’s most popular wheelchairs added a 20% surcharge to cover the cost of raw materials and freight for the product in the last four months alone. 

The costs for crutches have also gone up about 20%, although they have been hard to even get, she said. 

Meanwhile, exam tables, have gone up between 20 to 30% and are also backlogged about four to five months, according to Juhas. 

To underscore this issue, the American Hospital Association reported that between, the fall of 2020 and early 2022, the cost for energy, resins, cotton and most metals “surged in excess of 30%.” 

“These all are critical elements in the manufacturing of medical supplies and devices used every day in hospitals,” the AHA said. 

As a result, hospitals “turned to local suppliers and non-traditional suppliers, often paying significantly higher rates than they did prior to the pandemic.” 

GET FOX BUSINESS ON THE GO BY CLICKING HERE  

Some healthcare centers around the country even resorted to asking for donations for equipment.

Joey Kamerath, senior medical director for rehabilitation services at Intermountain Healthcare, said the department’s supply chain has run “completely dry.”

To help, Intermountain alongside University of Utah Health, Steward Health and the Utah Hospital Association created a program called LeanOnUtah in order to collect metal crutches, walkers, canes, and non-motorized wheelchairs.

medical equipment supply chain issues

CME obtains truckloads and truckloads of medical equipment at its warehouses around the country. (CME)

Likewise, Charleston Area Medical Center in West Virginia announced last fall that the pandemic and supply disruptions created a “nationwide shortage of adult crutches” and its vendors have been unable to fill orders. 

The medical center asked its Facebook followers “for anyone who may have crutches at home and not in use to consider donating them to patients,” adding that these donations “will help those who may need crutches when they are discharged from the hospital after an injury or surgery.”

Juhas projected that these issues – an increase in costs and shortage of supplies – will persist at least until the end of the year and maybe even into the first quarter of 2023. 

Inflation, supply chain shortages making it harder, more expensive to obtain needed medical equipment | Fox Business

Hospital expenses per inpatient day across 50 states

Ayla Ellison (Twitter)

Below are the adjusted expenses per inpatient day in 2020, organized by hospital ownership type, in all 50 states, according to the latest statistics from Kaiser State Health Facts

These figures, which are based on information from the 2020 American Hospital Association Annual Survey, include all operating and nonoperating expenses for registered U.S. community hospitals, defined as public, nonfederal, short-term general and other hospitals. The figures are an estimate of the expenses incurred in a day of inpatient care and have been adjusted higher to reflect an estimate of the volume of outpatient services, according to the Kaiser Family Foundation.

United States 

  • State/local government hospitals: $2,606
  • Nonprofit hospitals: $3,032
  • For-profit hospitals: $2,300 

Alabama

  • State/local government hospitals: $1,749
  • Nonprofit hospitals: $1,913
  • For-profit hospitals: $1,719 

Alaska

  • State/local government hospitals: $1,658 
  • Nonprofit hospitals: $2,156 
  • For-profit hospitals: $3,342 

Arizona

  • State/local government hospitals: $2,611
  • Nonprofit hospitals: $3,253 
  • For-profit hospitals: $2,804

Arkansas

  • State/local government hospitals: $2,713
  • Nonprofit hospitals: $1,852 
  • For-profit hospitals: $1,783 

California

  • State/local government hospitals: $3,886
  • Nonprofit hospitals: $4,464
  • For-profit hospitals: $2,708 

Colorado 

  • State/local government hospitals: $2,713 
  • Nonprofit hospitals: $3,633
  • For-profit hospitals: $3,153

Connecticut

  • State/local government hospitals: $5,557 
  • Nonprofit hospitals: $3,251 
  • For-profit hospitals: $2,287 

Delaware

  • State/local government hospitals: N/A
  • Nonprofit hospitals: $3,391 
  • For-profit hospitals: $1,122 

Florida

  • State/local government hospitals: $2,435
  • Nonprofit hospitals: $2,866 
  • For-profit hospitals: $2,111 

Georgia

  • State/local government hospitals: $779
  • Nonprofit hospitals: $2,420 
  • For-profit hospitals: $2,161 

Hawaii

  • State/local government hospitals: $1,916 
  • Nonprofit hospitals: $3,150 
  • For-profit hospitals: N/A

Idaho 

  • State/local government hospitals: $1,926 
  • Nonprofit hospitals: $3,169 
  • For-profit hospitals: $2,795 

Illinois

  • State/local government hospitals: $3,188 
  • Nonprofit hospitals: $2,939 
  • For-profit hospitals: $2,474 

Indiana

  • State/local government hospitals: $1,669 
  • Nonprofit hospitals: $3,243 
  • For-profit hospitals: $2,726 

Iowa

  • State/local government hospitals: $1,789 
  • Nonprofit hospitals: $1,791 
  • For-profit hospitals: $1,376 

Kansas

  • State/local government hospitals: $2,019 
  • Nonprofit hospitals: $2,263 
  • For-profit hospitals: $2,401 

Kentucky

  • State/local government hospitals: $2,440 
  • Nonprofit hospitals: $2,283 
  • For-profit hospitals: $2,286 

Louisiana

  • State/local government hospitals: $1,999 
  • Nonprofit hospitals: $2,496 
  • For-profit hospitals: $,2292

Maine

  • State/local government hospitals: $1,573 
  • Nonprofit hospitals: $2,967 
  • For-profit hospitals: $1,194 

Maryland

  • State/local government hospitals: N/A
  • Nonprofit hospitals: $3,344 
  • For-profit hospitals: $1,559 

Massachusetts

  • State/local government hospitals: $2,598 
  • Nonprofit hospitals: $3,651 
  • For-profit hospitals: $2,251 

Michigan

  • State/local government hospitals: $1,136 
  • Nonprofit hospitals: $2,787 
  • For-profit hospitals: $2,382 

Minnesota

  • State/local government hospitals: $2,065 
  • Nonprofit hospitals: $2,648 
  • For-profit hospitals: N/A

Mississippi

  • State/local government hospitals: $1,157 
  • Nonprofit hospitals: $1,424
  • For-profit hospitals: $1,728 

Missouri

  • State/local government hospitals: $2,147 
  • Nonprofit hospitals: $2,847 
  • For-profit hospitals: $2,097 

Montana

  • State/local government hospitals: $671 
  • Nonprofit hospitals: $2,060 
  • For-profit hospitals: $3,235 

Nebraska

  • State/local government hospitals: $1,510 
  • Nonprofit hospitals: $2,600 
  • For-profit hospitals: $3,141 

Nevada

  • State/local government hospitals: $3,179 
  • Nonprofit hospitals: $2,537 
  • For-profit hospitals: $2,186 

New Hampshire 

  • State/local government hospitals: N/A
  • Nonprofit hospitals: $3,238 
  • For-profit hospitals: $3,321

New Jersey 

  • State/local government hospitals: $1,922 
  • Nonprofit hospitals: $3,409 
  • For-profit hospitals: $2,250 

New Mexico

  • State/local government hospitals: $3,466 
  • Nonprofit hospitals: $3,259 
  • For-profit hospitals: $2,731

New York

  • State/local government hospitals: $3,800 
  • Nonprofit hospitals: $3,652 
  • For-profit hospitals: N/A

North Carolina

  • State/local government hospitals: $2,389 
  • Nonprofit hospitals: $2,603 
  • For-profit hospitals: $2,395 

North Dakota

  • State/local government hospitals: N/A 
  • Nonprofit hospitals: $1,788 
  • For-profit hospitals: $5,579 

Ohio

  • State/local government hospitals: $3,530 
  • Nonprofit hospitals: $3,245 
  • For-profit hospitals: $2,291 

Oklahoma

  • State/local government hospitals: $1,830 
  • Nonprofit hospitals: $2,243 
  • For-profit hospitals: $2,444

Oregon

  • State/local government hospitals: $4,855 
  • Nonprofit hospitals: $3,848 
  • For-profit hospitals: $3,290 

Pennsylvania 

  • State/local government hospitals: $926 
  • Nonprofit hospitals: $2,859 
  • For-profit hospitals: $2,210 

Rhode Island

  • State/local government hospitals: N/A
  • Nonprofit hospitals: $3,019 
  • For-profit hospitals: N/A

South Carolina

  • State/local government hospitals: $2,545 
  • Nonprofit hospitals: $2,352 
  • For-profit hospitals: $1,944 

South Dakota

  • State/local government hospitals: $812 
  • Nonprofit hospitals: $1,593 
  • For-profit hospitals: $4,788 

Tennessee

  • State/local government hospitals: $1,895 
  • Nonprofit hospitals: $2,671 
  • For-profit hospitals: $1,941 

Texas

  • State/local government hospitals: $3,639 
  • Nonprofit hospitals: $3,113 
  • For-profit hospitals: $2,274 

Utah

  • State/local government hospitals: $3,055 
  • Nonprofit hospitals: $3,609 
  • For-profit hospitals: $3,097 

Vermont

  • State/local government hospitals: N/A
  • Nonprofit hospitals: $3,114 
  • For-profit hospitals: N/A

Washington

  • State/local government hospitals: $4,294 
  • Nonprofit hospitals: $3,803 
  • For-profit hospitals: $4,707 

West Virginia

  • State/local government hospitals: $1,412 
  • Nonprofit hospitals: $2,289 
  • For-profit hospitals: $1,171 

Wisconsin

  • State/local government hospitals: $4,060 
  • Nonprofit hospitals: $2,725 
  • For-profit hospitals: $2,913

Wyoming

  • State/local government hospitals: $1,170 
  • Nonprofit hospitals: $3,546
  • For-profit hospitals: $2,612 

Hospital expenses per inpatient day across 50 states (beckershospitalreview.com)

Hospital drug spending jumps 8.4% in 2021

Katie Adams – Thursday, April 7th, 2022 

The country’s total drug spending increased by 7.7 percent in 2021, growing to $576.9 billion, according to a study released April 6 by the American Society of Health-System Pharmacists. 

Hospitals accounted for $39.6 billion of that spending, marking 8.4 percent growth from 2020. Clinics accounted for $105 billion, a 7.7 percent increase

Gilead’s COVID-19 therapeutic remdesivir made up nearly 10 percent of what hospitals spent on drugs in 2021. Hospitals’ remdesivir spending outpaced the next three drugs combined, according to the study.

“The drug-spending whiplash that clinics and hospitals experienced in the first year of the pandemic did not end with 2021,” Eric Tichy, PharmD, division chair of supply chain management at Rochester, Minn.-based Mayo Clinic and lead study author, said in a statement. “Uncertainty remains around how long the federal government will continue to pay for COVID treatments, and around inflation, which is moving through most economic sectors.”

Becker’s Hospital Review

Thermo Fisher Scientific to Support National Program to Accelerate SARS-CoV-2 Variant Identification

CARLSBAD, Calif., (March 23, 2022) Thermo Fisher Scientific Inc., the world leader in serving science, today announced its collaboration with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Initiative, Helix, and Rosalind aimed at developing a new genotyping method for SARS-CoV-2 that could speed up the identification of variants as they emerge.
 

Utilizing a Polymerase Chain Reaction (PCR)-based genotyping approach that can be implemented in any testing lab performing real-time PCR, this program allows for a significant scale up of SARS-CoV-2 surveillance efforts in the United States. Data generated from this program will be available to the public through the Rosalind Tracker website. This effort was funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) as part of the NIH RADx Initiative to increase testing capacity and accessibility for the virus that causes COVID-19.
 

The rapid emergence of new SARS-CoV-2 variants raises several important public health questions, such as their ability to cause disease and their impact on vaccine efficacy. This makes it critical to track variants to better understand transmission patterns and possible consequences on health care resources. Next-Generation Sequencing (NGS) is the conventional method for detecting and tracing new variants, with about 5 percent of randomly selected SARS-CoV-2 positive samples in the United States being sent for variant identification. NGS, however, can possibly take up to 21 days from a positive result before variant data is available in public repositories.
 

With the addition of genotyping, labs can classify a high percentage of positive samples and provide information within two to three days. They can also reduce costs for strain subtyping as compared to NGS. Samples that cannot be assigned to a known variant through the genotyping approach become prime candidates to detect new or emerging variants more rapidly. 
 

“As COVID-19 evolves with new variants constantly emerging, surveillance will play a critical role as we learn to live with the virus,” said Dr. Manoj Gandhi, senior medical director of genetic testing solutions, Thermo Fisher.
 

“Our approach makes it possible to conduct surveillance testing on a significantly larger number of samples and quickly determine which variant is present in a sample,” said Dr. Eric Lai, co-lead investigator of the NIH RADx initiative. “If we start seeing a trend where we are unable to assign lineages using known markers in the genotyping assays, it is an early warning that a new variant may be emerging and helps determine which samples should be sent for sequencing. This is significant because emerging variants have the potential to evade vaccines, cause diagnostic test performance issues, or cause more severe disease.”
 

A recent paper outlines the performance of this method for identifying markers and assigning lineages to several SARS-CoV-2 variants, including previously characterized Variants of Concern (VOC) such as Alpha, Beta, Gamma and Delta. In addition, the study describes how this approach can be rapidly adapted to develop a targeted panel for currently circulating strains, such as Delta and Omicron, to allow for large-scale surveillance in routine testing laboratories.
 

The rapid selection and validation of highly sensitive and specific biomarkers for SARS-CoV-2 variants was enabled with the ROSALIND platform during the collaborative initiative. This dynamic, cloud-based data analytics platform was able to act as a centralized tool for labs by aggregating and analyzing the data in a real-time dashboard format. Thermo Fisher has updated the TaqMan SARS-CoV-2 Mutation Panel* to include the four markers that can detect the Omicron and Delta variants with high precision. 
 

“Our challenge has been staying in front of this pandemic at the rate the virus is evolving. We’ve demonstrated an approach for maintaining highly accurate markers, rapidly implementing marker updates in manufacturing, and quickly deploying these assays to nationwide testing labs for validating COVID-19 positivity with lineage assignment,” said Tim Wesselman, CEO of Rosalind. “With a public tracking dashboard, this automated analysis, classification, and real-time genotyping reporting provides a snapshot of the most current strains circulating the country and provide us with valuable information to respond more quickly.”
 

“A robust early warning surveillance capability will eventually incorporate multiple layers of novel technologies,” said Dr. David Becker, vice president of quality at Helix and co-investigator of the program. “We were excited to explore, understand, and validate this technology that enables rapid reporting and increased surveillance of the SARS-CoV-2 variants in circulation.”
 

*For research use only. Not for use in diagnostic procedures.


About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Owens & Minor completes acquisition of Apria, Inc.

March 29, 2022 – Owens & Minor has closed the previously announced acquisition of Apria, Inc. The acquisition was consummated for total consideration in cash of approximately $1.6 billion. The purchase was funded with a combination of debt and cash on hand. 

The transaction combines the strength of Owens & Minor’s existing Byram Healthcare business with Apria to create an enhanced experience for the patient, provider and payor. The combined entity will create: 

  • One of the broadest portfolios of complementary products to service patients with chronic and non-chronic conditions 
  • An expanded product delivery and distribution model 

Apria will be combined with Owens & Minor’s existing Byram Healthcare business to form the new Patient Direct segment. This new segment creates a robust commercial team with greater access to patients across a wider geographic footprint. It also expands Owens & Minor’s home healthcare portfolio to cover an unmatched range of chronic and acute care needs including diabetes, ostomy, incontinence, wound care, home respiratory, obstructive sleep apnea and negative pressure wound therapy. The company will leverage its existing market reach and expertise in the hospital setting to create a more efficient, single-source home healthcare delivery and distribution model to support patients as their care transitions from the hospital into the home. 

Daniel J. Starck, who has served as Chief Executive Officer for Apria since 2015, has joined Owens & Minor and will lead the new Patient Direct segment. 

“We look forward to unleashing the full potential of our teammates in the new Patient Direct segment to achieve even better clinical connectivity between the patient, the provider and the payor,” said Daniel J. Starck, Executive Vice President, President-Patient Direct, Owens & Minor. 

Beginning in the first quarter of 2022, Owens & Minor will change its reporting structure to reflect the company’s go-to-market approach. The two legacy segments will be replaced with two new segments: Patient Direct and Products & Healthcare Services. Patient Direct will be a combination of Byram and Apria, while Products & Healthcare Services will be a combination of the global products, medical distribution and services businesses. The company will release a historical recast for 2021, by quarter, ahead of reporting first quarter 2022 earnings. 

Learn More 

Filed Under: Repertoire’s Dail-eNews

Inflation and the healthcare supply chain: What you need to know

There’s no getting around it. Inflation has permeated every aspect of the economy – including the healthcare supply chain. Raw materials, energy, labor and logistics have all been affected, said Margaret Steele, Vizient Senior Vice President, Med/Surg.  

Indeed, over the 12 months from February 2021 to February 2022, the Consumer Price Index, which measures the average prices of consumer goods and services, increased 7.9% to a four-decade high.  

Labor costs rose 4% to 8% with manufacturers and freight companies struggling to attract workers and drivers. In the healthcare sector, escalating labor costs have been particularly painful. In its February National Hospital Flash Report, Kaufman Hall found that from December to January labor expense per adjusted discharge climbed 14.6%. 

Through the last year and a half (since fall 2020) energy, resins, cotton and most metals have all surged in excess of 30%. “With the recent upturn of oil prices, the rate of inflation will continue this upward trend,” Steele said. “These levels of inflation are impacting manufacturers and service providers significantly and they have begun raising prices on the supplies, equipment, and services they deliver to hospitals.” 

Global events hit home 

Steele said the healthcare supply chain has been significantly impacted over the last several years due to many factors including world events. As a result, timely and accurate information is critical to minimize impact and determine risk mitigation strategies.  

“Supply chain leaders use various tools, such as budget impact projection reports, market supply updates and category specific insights, to understand the impact of changes affecting raw materials, labor and logistics as they look to understand cost and risk for supply disruption,” Steele said. Now, supply chain leaders are utilizing these same sources to monitor the impact of the recent events that also have an impact on raw materials, manufacturing and transportation.  

Steele projects the most impactful and of most interest will likely be oil as so many products contain some form of plastic or resin (a derivative of oil). In mid-March, resin prices remained higher than pre-COVID levels and were expected to remain so as long as oil remains near or above $80 per barrel and producers continue struggling to get resins moved through the supply chain. Both issues are anticipated to remain through most of 2023. Oil price fluctuation, trucker shortages and port backups will also impact the costs for transporting products to the provider locations.  

“Many products have not yet been impacted as the situation is affecting raw materials,” Steele said. “That said, impact mitigation strategies vary by location and provider type. Providers are sharing conservation strategies in efforts to reduce usage as appropriate, pre-qualifying alternative products in the event of a disruption, increasing product on hand (or at a distributor/partner location) and ensuring product is sourced from a variety of locations. Several suppliers have medical teams that will work with the providers directly to discuss alternative uses. And, many are also participating in commitment programs, wherein suppliers and providers agree on a longer, committed supply and in some cases pricing.” 

While GPO and self-negotiated contracts are keeping prices fairly stable at the moment, supply chain leaders fully expect to see significant price increases in the next series of contracts, said Mike Schiller, senior director of supply chain at the Association for Health Care Resource & Materials Management (AHRMM) of the American Hospital Association (AHA).  

“Many are anticipating high single to low double digit price increases and have begun to include these into their budgetary considerations.” 

Filed Under: Repertoire’s Dail-eNews

Thermo Fisher Scientific RT-LAMP Tests Simplify Infectious Disease Surveillance

Low-cost kits help global public health professionals quickly identify potential outbreaks

CARLSBAD, Calif., March 9, 2022 – To support active research and surveillance of viral pathogens, including SARS-CoV-2, Thermo Fisher Scientific has launched two new reverse transcription loop-mediated isothermal amplification (RT-LAMP)-based solutions. While PCR remains the gold standard for diagnostic, lab-based testing, isothermal RT-LAMP nucleic-acid-based amplification provides a rapid and low-cost option for viral pathogen detection.

“In the global fight against COVID-19 and future infectious disease outbreaks, researchers need cost-effective, easy-to-use solutions for rapid detection of viral pathogens,” said Dale Patterson, vice president and general manager of molecular biology at Thermo Fisher Scientific. “With RT-LAMP technology, researchers can accurately detect the presence of a pathogen by seeing a simple color change with the naked eye. Our new solutions enable frequent – even daily – surveillance without complex instrumentation or highly trained staff, making them ideal tools to support community surveillance in resource-constrained areas.”

The Invitrogen Colorimetric ReadiLAMP Kit, SARS-CoV-2* is an off-the-shelf assay designed to provide accurate, robust detection of SARS-CoV-2 from saliva, nasal or nasopharyngeal swab samples. The kit includes two protocols: a rapid, 30-minute turnaround time for crude sample types, which reduces reagents use and costs by eliminating the need for nucleic acid isolation, or a one-hour turnaround time for increased sensitivity with purified RNA sample types.

“Thermo Fisher is committed to expanding access to solutions to aid global SARS-CoV-2 surveillance efforts as the world continues to monitor for new variants,” said Ellie Mahjubi, vice president and general manager of sample preparation at Thermo Fisher Scientific. “For instance, we have introduced modified workflows that use room-temperate stable reagents to eliminate the need for cold storage. We are also gathering data on pooling samples to provide a highly affordable option for reliable population-level infectious disease monitoring that could be easily deployed anywhere in the world, including in developing countries.”  

For infectious disease researchers looking to research or develop their own assays for a range of applications, the Invitrogen SuperScript IV RT-LAMP Master Mix* provides fast and sensitive detection of viral pathogens, including SARS-CoV-2, measles and influenza, in as little as five minutes. The optimized master mix uses robust enzymes and is compatible with multiple methods for evaluating results, offering the flexibility to optimize assay development for a variety of RNA and DNA targets and concentrations.

To learn more about the Colorimetric ReadiLAMP Kit and SuperScript IV RT-LAMP Master Mix, visit thermofisher.com/rtlamp.

*For research use only. Not for us in diagnostic procedures.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.


Media contact information:

Mauricio Minotta

760-805-5266

mauricio.minotta@thermofisher.com

Jen Heady

413-237-5141

jheady@greenough.biz


SOURCE Thermo Fisher Scientific

If you have any questions regarding this Press Release, please email us at media.relations@thermofisher.com.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.


Media contact information:

Mauricio Minotta

760-805-5266

mauricio.minotta@thermofisher.com

Jen Heady

413-237-5141

jheady@greenough.biz


SOURCE Thermo Fisher Scientific

If you have any questions regarding this Press Release, please email us at media.relations@thermofisher.com.


Mask mandates dropped in every state: 3 pandemic updates

Erica Carbajal

Hawaii Gov. David Ige on March 8 announced the state would lift its universal indoor mask mandate March 26, making it the final state to do so, The New York Times reports. 

“We have reduced COVID-19 in a way to the point where most of us will be safe without masks indoors,” Mr. Ige said during a press conference.

The move is an abrupt pivot from a week ago, when the governor said the mask mandate would remain in place as other restrictions, such as the state’s entry requirements for travelers, were dropped. Hawaii held onto its mask mandate longer than most of the country because “we are willing to sacrifice to keep each other healthy and safe,” Mr. Ige said. Masks will remain a requirement indoors at public schools in the state. 

The CDC on March 3 provided an update on its new mask guidance, saying more than 90 percent of the U.S. population now live in areas with low or medium COVID-19 community levels, indicating masks are not needed. 

Two more updates: 

1. In a reversal, the World Health Organization on March 8 expressed support for COVID-19 boosters shots. The organization’s Technical Advisory Group on COVID-19 Vaccine Composition said in a statement it “strongly supports urgent and broad access to current COVID-19 vaccines for primary series and booster doses, particularly for groups at risk of developing severe disease.” 

In August 2021, the WHO called for an international moratorium on booster doses as primary vaccination rates remained low in vulnerable countries. In its latest update, the agency said, “The near- and medium-term supply of the available vaccines has increased substantially; however, vaccine equity remains an important challenge and all efforts to address such inequities are strongly encouraged.” 

2. In a move “toward the endemic phase of the pandemic,” the Oklahoma State Department of Health is ending daily COVID-19 reports that provided updates on new cases, COVID-19 hospitalizations and death tolls. The state will now shift to a weekly report on Thursdays, according to a March 7 news release. The shift will allow the health department to “focus on key metrics that more accurately represent the impact of disease in the community, like hospitalizations.”

All the World’s a Stage

Pandemic proves that healthcare logistics demands a global perspective

By Mark Thill

A year ago, were you aware of the term “dwell time?” Did the word “container” connote anything other than Tupperware? Did you know how many weeks in a typical month an over-the-road trucker is away from home? Had you ever stopped at the Corwith Yards on the Southwest Side of Chicago to see what goes on at a railroad intermodal freight terminal?

How quickly would you have made the connection between a resin factory fire in Texas and the availability and price of medical products? How about a cold spell in the Lone Star State, a hurricane in Puerto Rico, a cargo ship stuck in the Suez Canal, a drought in Taiwan affecting microchip production, or a virus causing concern among authorities in a Chinese city named Wuhan?

Due to world events of the past 24 months, healthcare supply chain executives are finding that what they once took for granted, what they learned from the logistics gurus, doesn’t necessarily work during pandemics.

“PPE supply was the biggest challenge for 2020,” says Mark Henderson, senior vice president of sales and marketing for Concordance Healthcare Solutions. “The issues in 2021 have been much broader, as it is not just about aligning supply and demand, but rather the challenges related to getting product from the manufacturers to the distributors and providers. You can have an accurate picture of product needs and manufacturing volumes, but if you cannot get product from point A to point B in a timely fashion, you have an issue.”

Getting products from point A to point B ain’t what it used to be. The question is, will it ever return to “normal?” Based on comments gathered by Repertoire, even if we don’t see a full-blown paradigm shift, we will see changes, especially:

  • Advances in visibility – transparency – across the supply chain.
  • Creative ways to store products, such as 3PLs or what one distributor calls “living stockpiles.”
  • Increased attentiveness to alternative or substitute products, just in case.

The situation

“Things are more difficult now than at any other point in the pandemic,” Abby Pratt, senior vice president for global strategy and analysis for AdvaMed, the medical manufacturers association, told Repertoire in December. (The Advanced Medical Technology Association, or AdvaMed, represents companies that produce medical devices, diagnostic products and digital health technologies.) “In the early stages, it was limited to things like PPE and COVID technologies. But now, delays, bottlenecks and disruptions are making headlines, just as they are in every other sector. It’s not only affecting products and materials imported into the United States, but also raw materials, supplies and components that are coming into the U.S. for manufacturing and production in this country.”

James Sembrot, senior vice president, U.S. Supply Chain, Cardinal Health, says, “As an industry, the supply chain is facing increased global demand for product and movement of product, primarily from Asia-Pacific to the United States. Additionally, the supply chain is encountering container shortages, port congestion and operational constraints, vessel availability challenges, disruptions in shipping schedules and increased wait times, labor shortages and heightened shipping costs.”

Ocean freight delays and raw material inflation have caused significant constraints, adds Robert Rajalingam, president, U.S. Medical Products and Distribution, Cardinal Health. “Resins, corrugate and metals have experienced significant cost increases. Because of the winter storm impacts, and prior to that, the fire at the resin manufacturer, Total Petrochemicals, we’re dealing with a market that’s been constrained for well over a year.

“During a global pandemic environment and with many manufacturers on allocation, the challenges compound,” he says. “Plus, resin is not only used to form plastics, like sharps containers, but it is also used in non-woven fibers, tubing, flexible packaging, etc.”

Container costs have grown to eight times the normal rates, he says. Over a recent 12-month period, Cardinal Health spent $48 million on charters to bring in product from Asia. “But this system is not cost effective and not a long-term strategy.”

A crisis by any other name

“Part of the definition of ‘crisis’ is a time of great difficulty,” says Henderson. “Personally, I prefer to think of it as a tremendous challenge that we will need to resolve collaboratively across suppliers, distributors, providers, logistics organizations and state and local agencies. Any supply chain that has a patient at the end of it needs to be prioritized.”

The difference between 2020 and 2021? “I’m not sure I would call [the current situation] a crisis anymore, as it was in 2020,” says Steve Martin, senior vice president of supplier management for Nashville-based NDC Inc. “Product is moving. It’s just moving slower and at a much higher cost. Supply chain issues have negatively impacted our fill rates as we still have a significant number of products that continue to be on allocation or in short supply. Also, the increase in lead times from suppliers makes it difficult to quickly react to changes in product demand from our distributors.

“The rising cost of freight across all modes has significantly impacted the cost to serve suppliers, NDC and our distributors,” he continues. “We have seen unprecedented increases in product costs, sometimes appearing as an ‘order surcharge,’ which is directly related to the global and national supply chain issues.”

Supply chain and clinical professionals may not be using the word “crisis” to describe the current situation, but they are definitely in pandemic mode, says Mike Schiller, senior director of supply chain for the Association for Health Care Resource & Materials Management of the American Hospital Association. In addition to sourcing supplies through traditional channels, they are diversifying vendor portfolios and employing conservation and utilization strategies.

Two years into the pandemic, the industry has moved beyond PPE-only shortages to shortages in other business sectors that are directly or indirectly affecting the healthcare supply chain, he says. These include:

  • Semiconductors: As of late December, shortages were causing 9-to-12-month equipment delays.
  • Aluminum products (crutches, walkers, canes): In response, some organizations are seeking donations from the community.
  • Blood collection tubes: Varying, rolling backorders. Solutions and conservation strategies include using EMRs to view and manage orders, review blood draw requests.
  • Pediatric supplies (e.g., diapers, formula, nipples, small French urine collection catheters, butterfly needles and umbilical cord catheters, neonate blood pressure cuff size 4, cardiac leads). Solutions include purchasing individual components – urine specimen cups, sticks, wipes, etc. – and assembling kits, exploring reuse of disposable blood pressure cuffs or moving to reusable cuffs.
  • Resin products (e.g., suction canisters, sharps containers, soap containers, decontam wipes tubs, hand soap and foaming soap dispensers). Solutions include exploring reusable sharps containers.

Inflation is another concern, says Schiller. Although GPO and other contract pricing has remained relatively stable throughout the pandemic, supply chain professionals can expect increases due to supply/logistics demand and constraints, new supply and multisource contracts, and diversified vendor portfolios. “We are encouraging supply chain leaders and healthcare organizations to explore other non-labor cost-savings opportunities, with a key area being purchased services.”

Visibility

A common theme among supply chain executives is the need for greater visibility across the supply chain. But given the many constituencies involved – raw materials suppliers, factories, ocean carriers, railroads, trucking firms, med/surg distributors and health systems – that won’t be easy.

“Raising the bar on accuracy and visibility of data from suppliers is critical as we move forward,” says Henderson. “Combined with visibility to our on-hand inventories and demand signals from customers, we can move toward a proactive supply chain powered by actionable information. Automating this process … is key.”

In November, AdvaMed, the Health Industry Distributors Association (HIDA) and International Safety Equipment Association (ISEA) announced they were collaborating with port leaders to test processes for prioritizing medical supply containers. The organizations have engaged the Federal Maritime Commission and the White House Supply Chain Disruption Task Force in their efforts.

“But we have to approach it terminal operator by terminal operator, because they are not interoperable,” says Pratt. “There’s no single system spanning all these different actors. That’s why we are looking at greater interoperability and visibility.”

Curtis Lancaster, chief supply chain officer, Westchester Medical Center Health Network (WMCHealth), Valhalla, New York, says the health system’s supply chain team collaborates regularly with its clinicians and distribution partners, and uses AI-powered software to identify global trends that may affect the supply chain. “We also collaborate with onshore and near-shore partners that reduce our reliance on offshore suppliers,” he says. WMCHealth comprises 10 hospitals and includes an academic medical center, acute care children’s hospital, multiple community hospitals, skilled nursing facilities and two practices with over 850 providers.

Cardinal Health is making “significant investments in technology to drive greater visibility, sustainability and resiliency,” says Rajalingam. In March 2020, the company began working with freight-tracking software startup FourKites Inc. on a pilot to track shipments of personal protective equipment between manufacturing plants and the company’s distribution centers.

Centralized advanced planning data allows those in the supply chain to jointly conduct forecasting and supply chain simulations and plan alternative options, says Rajalingam. “It also drives network inventory optimization.

“Through extensive collaboration with leading 3PL organizations, we are expanding access to secure equipment (i.e., containers), capacity and alternative routes; increasing visibility to enable quick, data-backed decision-making; increasing visibility to the location of shipments across oceans, through ports, etc.; and managing supply chain costs.”

No paradigm shift on JIT

Choke points, logjams and bottlenecks notwithstanding, healthcare supply chain experts aren’t predicting a widespread about-face on just-in-time. “I don’t think you’ll see a paradigm shift,” says Pratt. “Companies will do more to invest in risk mitigation and might build these learnings into their processes, but when things normalize, they will want to be efficient.” That holds true for products that are perishable as well as those in which innovation occurs rapidly. “If you stockpile too much, you will have some obsolescence. So it’s a balance.”

Concordance Healthcare Solutions found 3PL storage to be in high demand during 2020 and into 2021, says Henderson. “Much of this was PPE products, but the service can apply across any category. We will continue to ramp up these programs for both providers and suppliers to increase access to products.”

Says Mike Schiller, “Just-In-Time, Low Unit of Measure and Lean principles will need to be re-evaluated across the entire supply chain continuum. COVID has highlighted our need for more transparency, robust analytics and improved utilization data – the capture of product use at the point of consumption.” Moving from par inventories to demand planning, where possible, may help achieve better alignment between on-hand inventory levels and actual use.

Solutions

Charlotte Perkins, interim vice president of supplier and portfolio management for Owens & Minor, says the company’s Americas-based manufacturing has helped maintain the supply of personal protective equipment throughout the pandemic. “We manufacture our own raw materials in North Carolina and convert them into N95 respirators, isolation gowns, surgical gowns, ear loop masks and other PPE in our plants in Texas, Mexico and Honduras.”

In addition to self-manufactured products, Owens & Minor partners with more than 1,000 branded manufacturers. “We have recently seen minor supply chain challenges with IV solutions and syringes, as well as a slight increase in demand for IV catheters,” says Perkins, adding that the company’s allocation practices have enabled it to fulfill demand even during the peak of the pandemic.

For more than 10 years, Owens & Minor has provided an outsourced logistics offering to help customers address pandemic storage requirements and to manage supply streams from multiple sources, she adds. In 2020, the company expanded this capability across the entire network, with more than 25 Owens & Minor distribution centers now actively delivering Outsourced Logistics services. In addition, Owens & Minor clients can now subscribe to alerts via the SMART Card (Supplier Metrics & Accountability Report Tracker) for bi-weekly snapshots and updates, keeping them aware of product constraints or supply chain disruptions.

Steve Martin says the NDC team has devised several solutions to help members maintain an adequate supply of products and equipment, including:

  • Distributor allocations based on historical demand or as directed by suppliers.
  • Lead time adjustments from suppliers to accommodate supply chain issues, sometimes increasing the amount of stocked inventory to account for longer lead times.
  • Careful review of new business opportunities on products that have longer lead times to protect NDC’s ability to service existing business from distributors.

“NDC doesn’t manage the inbound logistics of shipments from suppliers, which is managed by the suppliers themselves,” says Martin. “So it is important for us to be well informed of the status of inbound containers or shipments. Many suppliers have established regularly occurring calls with NDC to review the status of containers/shipments, update production lead times, review product allocations, and provide general business updates.”

Many NDC members have established multiple supplier relationships for impacted products, where possible, he adds. “Some members have begun sourcing more products directly from manufacturers to increase their control over product visibility and access. This includes looking at alternative ports of entry for products that source via ocean freight.

“Many NDC distributors are also working with their provider customers to encourage them to increase their safety stock on critical items. Some have expanded existing warehouse space and/or added warehouses in strategic geographical areas, so they can provide stockpile services to their provider customers.”

Cardinal Health’s Robert Rajalingam says that the company is actively lobbying Capitol Hill with other industry associations for resolution of the current backup of medical products. “We are also working with the federal government to prioritize releasing backlogged containers with critical medical supplies. Plus, we’ve had a high level of involvement with HIDA and AdvaMed, as well as the ports of Los Angeles and Long Beach and the Federal Maritime Commission, to structure a broad-based prioritization process for identifying and expediting critical medical supplies through the ports.”

Says AHRMM’s Mike Schiller, “Moving forward, successful supply chain professionals will need to possess a global acumen, understanding how disruptions, like raw material shortages, labor, political unrest, etc., may impact their supply chains. They will need to remain strategic and reduce or eliminate risk from their supply chains through deeper collaboration with existing suppliers while looking to build relationships with local and community businesses.”